pyrazolanthrone has been researched along with Leukemia, Promyelocytic, Acute in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuchi, H; Takagi, N; Toyoda, H; Yuan, B; Yuhara, E | 1 |
| Breslin, P; Chen, J; Kuo, PC; Li, J; Li, X; Li, Z; Liu, X; Nand, S; Schmidt, R; Volk, A; Wei, W; Xiao, Y; Xin, J; You, D; Zhang, J; Zhang, Z | 1 |
2 other study(ies) available for pyrazolanthrone and Leukemia, Promyelocytic, Acute
| Article | Year |
|---|---|
Involvement of histone H3 phosphorylation through p38 MAPK pathway activation in casticin-induced cytocidal effects against the human promyelocytic cell line HL-60.
Topics: Adenosine Triphosphate; Anthracenes; Antioxidants; Apoptosis; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Histones; HL-60 Cells; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; M Phase Cell Cycle Checkpoints; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Reactive Oxygen Species | 2013 |
Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML.
Topics: Animals; Anthracenes; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Mice; Mice, Knockout; NF-kappa B; Nitriles; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sulfones; Transcription Factor AP-1; Tumor Necrosis Factor-alpha; U937 Cells | 2014 |